loading page

AMBULATORY MICRO-DOSE INDUCTION OF BUPRENORPHINE-NALOXONE IN TWO ADOLESCENT PATIENTS WITH SICKLE CELL DISEASE
  • +1
  • Bradley Buchheit,
  • Timothy Joslin,
  • Helen TurnerOrcid,
  • Trisha E. Wong
Bradley Buchheit
Oregon Health & Science University
Author Profile
Timothy Joslin
Oregon Health & Science University
Author Profile
Helen Turner
Orcid
Oregon Health & Science University
Author Profile
Trisha E. Wong
Oregon Health & Science University
Author Profile

Peer review status:UNDER REVIEW

08 Jun 2020Assigned to Editor
08 Jun 2020Submission Checks Completed
08 Jun 2020Submitted to Pediatric Blood & Cancer
15 Jun 2020Reviewer(s) Assigned

Abstract

Sickle cell disease (SCD) is a hematologic disorder defined by presence of sickle-shaped red blood cells that can occlude blood vessels and cause tissue ischemia and pain. Treating SCD pain adequately and safely is difficult given today’s opioid climate. Buprenorphine-naloxone is described in adult literature where it typically requires withdrawal of full-agonist opioids and inpatient hospitalization. Here we present two adolescents with SCD who successfully weaned off large doses of full-agonist opioids by using micro-dose induction of buprenorphine-naloxone in clinic. Ambulatory micro-dose induction may remove hurdles that otherwise would discourage patients from trying this regimen while still controlling pain safely.